# Verapamil for Neuroprotection in Stroke

> **NCT03347786** · PHASE1,PHASE2 · RECRUITING · sponsor: **Global Neurosciences Institute** · enrollment: 60 (estimated)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** 10 mg Intra-arterial Verapamil
- **DRUG:** 20 mg Intra-arterial Verapamil

## Key facts

- **NCT ID:** NCT03347786
- **Lead sponsor:** Global Neurosciences Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-04-20
- **Primary completion:** 2026-08
- **Final completion:** 2026-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03347786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03347786, "Verapamil for Neuroprotection in Stroke". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03347786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*